Lesson of the month 1: Septic arthritis with normal acute phase reactants and white cell count in a patient receiving tocilizumab

Authors: Richard Conway, Carl Orr and Geraldine M McCarthy

Septic arthritis represents 8–27% of cases of monoarthritis presenting to the emergency department. Tocilizumab is an interleukin-6 blocking monoclonal antibody with the mechanistic potential to interfere with the body’s normal inflammatory response to an infectious insult. We present a case of septic arthritis with a normal white cell count, C-reactive protein, erythrocyte sedimentation rate and fibrinogen in a patient treated with tocilizumab.

Case history
A 70-year-old builder with known rheumatoid arthritis, hypertension, ischaemic heart disease and bilateral total hip replacements presented to the rheumatology clinic with acute monoarthritis of his left knee. Severe pain meant he had great difficulty bearing weight. His rheumatoid arthritis was being treated with methotrexate 20 mg orally and tocilizumab 162 mg subcutaneously weekly and had been in remission at his previous clinic visit. He reported sustaining two superficial grazes on his left knee while kneeling at work on a building site 2 days previously. On examination, there was a large tense left knee effusion (Fig 1). The remainder of the joints were normal and he was afebrile. White cell count (WCC) was 7.44×10^9/L, neutrophils 4.77×10^9/L, erythrocyte sedimentation rate 2 mm/hour, C-reactive protein <1 mg/L and fibrinogen 2.8 g/L. Aspiration of the left knee yielded 90 cc of group 3 pyarthrosis. Synovial fluid WCC was >50,000, neutrophil recruitment. The inhibition of such a pleiotropic cytokine has the potential to cause significant perturbation in the normal immune response. However, the complete absence of any identifiable systemic immune response – as demonstrated in our case – is distinctly unusual. Despite the lack of elevation in laboratory parameters, our patient mounted a profound local immune response to the infection as shown by the recurrent large volume pyarthrosis. The portal of entry of infection was most likely the grazes overlying the knee joint. Our case highlights the need for sound clinical judgement rather than an overreliance on laboratory tests in assessing for septic arthritis in patients treated with tocilizumab.

Discussion
Septic arthritis is a medical emergency. Delay in treatment results in progressive joint destruction and increased difficulty clearing the infection. Tocilizumab is a humanised monoclonal antibody against the interleukin-6 receptor. In common with other biologic agents used in rheumatoid arthritis, tocilizumab is associated with a modest increase in the risk of infection with a relative risk of 1.82 compared with placebo. Tocilizumab also modulates the systemic response to infection through its inhibitory effect on interleukin-6 dependent pathways. Interleukin-6 is a potent stimulant for the synthesis and release of C-reactive protein and fibrinogen from the liver. Interleukin-6 is also a key participant in both lymphocyte differentiation and neutrophil recruitment. The inhibition of such a pleiotropic cytokine has the potential to cause significant perturbation in the normal immune response. However, the complete absence of any identifiable systemic immune response – as demonstrated in our case – is distinctly unusual. Despite the lack of elevation in laboratory parameters, our patient mounted a profound local immune response to the infection as shown by the recurrent large volume pyarthrosis. The portal of entry of infection was most likely the grazes overlying the knee joint. Our case highlights the need for sound clinical judgement rather than an overreliance on laboratory tests in assessing for septic arthritis in patients treated with tocilizumab.

Learning points
- Septic arthritis can occur in the absence of any elevation of WCC, acute phase reactants or fever in tocilizumab-treated patients.

© Royal College of Physicians 2017. All rights reserved.
Clinicians should maintain a high index of suspicion and recognise that lesser degrees of clinical and serological abnormality may herald severe sepsis in tocilizumab-treated patients.

Conflicts of interest
The authors have no conflicts of interest to declare.

Acknowledgements
The patient gave permission for publication of the clinical details and images in this article.

References
1. Woo P, Humphries SE. IL-6 polymorphisms: a useful genetic tool for inflammation research? J Clin Invest 2013;123:1413–4.
2. Strand V, Ahadieh S, French J et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther 2015;17:362.
3. Rincon M. Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. Trends Immunol 2012;33:571–7.

Address for correspondence: Dr Richard Conway, Department of Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland.
Email: drrichardconway@gmail.com